Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985-Reference-Cited by-同舟云学术

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Published:2015-02-18 Issue:6 Volume:12 Page:1813-1835
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Elgersma Ronald C.¹,Coumans Ruud G. E.¹,Huijbregts Tijl¹,Menge Wiro M. P. B.¹,Joosten John A. F.¹,Spijker Henri J.¹,de Groot Franciscus M. H.¹,van der Lee Miranda M. C.¹,Ubink Ruud¹,van den Dobbelsteen Diels J.¹,Egging David F.¹,Dokter Wim H. A.¹,Verheijden Gijs F. M.¹,Lemmens Jacques M.¹,Timmers C. Marco¹,Beusker Patrick H.¹

Affiliation:

1. Departments of †Medicinal & Protein Chemistry, ‡Preclinical, and §New Molecular Entities, Synthon Biopharmaceuticals BV, Microweg 22, 6545 CM Nijmegen, The Netherlands

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/mp500781a

Reference64 articles.

1. Advancing Antibody Drug Conjugation

2. Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

3. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

4. Antibody–drug conjugates: current status and future directions

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

2. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions;Pharmacological Research;2024-09

3. Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development;Drug Discovery Today;2024-08

4. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08

5. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22